je.st
news
Tag: receives
Detcon's Model X40 Controller Receives TUV Certification
2014-01-01 06:00:00| Industrial Newsroom - All News for Today
The Woodlands, TX — Detcon, an IST company, is pleased to announce that the Model X40 NEMA 4X alarm and control system has received cTUVus NRTL certification for non-hazardous locations. The rugged, power-efficient controller, designed to monitor gas detection sensors and a wide range of other field devices, can receive and supervise 4-20mA or RS-485 field device inputs. The controller can be customized and expanded to monitor up to 32 field devices using Detcon’s stackable ...This story is related to the following:Controls and ControllersSearch for suppliers of: Programmable Logic Controllers (PLC) | Gas Detectors
Tags: model
certification
controller
receives
01.03.14 -- Metso Receives Repeat Order For Automation Technology
2013-12-31 00:53:08| plantautomation News Articles
01/03/14Plant Automation.com Newsletter
Tags: order
technology
repeat
receives
Genzyme Receives Complete Response Letter from FDA on Lemtradaa (alemtuzumab) Application
2013-12-30 08:58:17| Biotech - Topix.net
Genzyme , a Sanofi company , announced today that it has received a Complete Response Letter from the U.S. Food and Drug Administration for its supplemental Biologics License Application seeking approval of Lemtrada for the treatment of relapsing forms of multiple sclerosis.
Tags: complete
application
response
letter
Rexahn Receives Method Patent For Treatment Of Solid Tumor Cancers For Supinoxin (RX-5902)
2013-12-30 06:54:32| drugdiscoveryonline News Articles
Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company developing potential best-in-class oncology therapies, recently announced that it has been issued United States Patent, No. 8,598,173, which covers a method for treating solid cancer tumors including ovarian, breast, prostate, liver, lung, kidney, colon, pancreatic and stomach for its clinical development candidate Supinoxin (RX-5902)
Tags: method
treatment
solid
patent
Athersys' MultiStem(R) Stem Cell Therapy Receives Orphan Drug Designation In Europe For Prevention Of Graft-Versus-Host Disease
2013-12-30 06:10:10| drugdiscoveryonline Home Page
Athersys, Inc. (Nasdaq:ATHX) announced today that the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA) has issued a positive opinion (EMA/OD/146/13) for the Company's allogeneic, multipotent adult progenitor cell, or MultiStem® therapy, for the prevention of graft-versus-host disease (GvHD)
Tags: europe
cell
drug
disease
Sites : [687] [688] [689] [690] [691] [692] [693] [694] [695] [696] [697] [698] [699] [700] [701] [702] [703] [704] [705] [706] next »